ミトブロニトール
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/11/17 01:25:17」(JST)
[Wiki en表示]
Mitobronitol
|
| Names |
Preferred IUPAC name
1,6-Dibromo-1,6-dideoxy-D-mannitol[citation needed]
|
Systematic IUPAC name
1,6-Dibromohexane-2,3,4,5-tetrol[1]
|
| Identifiers |
|
CAS Number
|
488-41-5 (2S,3S,4S,5S)-2,3,4,5-tetrol Y |
| ChEMBL |
ChEMBL161657 Y
ChEMBL447629 Y |
| ChemSpider |
4063 Y
5145112 (2S,3S,5R)-2,3,5-triol Y
5145112 (2R,3R,4R,5R)-2,3,4,5-tetrol Y |
| ECHA InfoCard |
100.006.979 |
| EC Number |
207-676-8 |
| Jmol 3D model |
Interactive image |
| KEGG |
D02020 Y |
| MeSH |
Mitobronitol |
| PubChem |
4208
44119013 (2R,3R)-2,3-diol
6713087 (2S,3S,5R)-2,3,5-triol
2794952 (2R,3R,4R,5R)-2,3,4,5-tetrol
656655 (2S,3S,4S,5S)-2,3,4,5-tetrol |
| RTECS number |
OP2800000 (2RS,3RS,4RS,5RS)-2,3,4,5-tetrol |
| UNII |
5UP30YED7N Y |
InChI
-
InChI=1S/C6H12Br2O4/c7-1-3(9)5(11)6(12)4(10)2-8/h3-6,9-12H,1-2H2 Y
Key: VFKZTMPDYBFSTM-UHFFFAOYSA-N Y
|
|
|
| Properties |
|
Chemical formula
|
C6H12Br2O4 |
| Molar mass |
307.97 g·mol−1 |
| Appearance |
Colourless crystals |
| log P |
−0.226 (2RS,3RS,4RS,5RS)-2,3,4,5-tetrol |
| Acidity (pKa) |
12.609 (2RS,3RS,4RS,5RS)-2,3,4,5-tetrol |
| Basicity (pKb) |
1.388 (2RS,3RS,4RS,5RS)-2,3,4,5-tetrol |
| Pharmacology |
|
ATC code
|
L01AX01 (WHO) |
| Related compounds |
|
Related compounds
|
- 1,2-Dibromopropane
- 1,3-Dibromopropane
- 1,2,3-Tribromopropane
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
| Infobox references |
|
|
Mitobronitol (1,6-dibromo-1,6-dideoxy-D-mannitol) is a brominated analog of mannitol. It is an anticancer drug that is classified as an alkylating agent.[2]
References
- ^ "Mitolactol - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 25 March 2005. Identification. Retrieved 22 June 2012.
- ^ Mitobronitol, The Centre for Cancer Education
English Journal
- [Tibor Vályi-Nagy (1912-1969), professor and researcher of pharmacology, was born one hundred years ago].
- Kovács P.
- Orvosi hetilap.Orv Hetil.2012 Jun 3;153(22):869-72. doi: 10.1556/OH.2012.HO2411.
- PMID 22641263
- Multiple granulocytic sarcomas in essential thrombocythemia.
- Tanaka Y1, Nagai Y, Mori M, Fujita H, Togami K, Kurata M, Matsushita A, Maeda A, Nagai K, Tanaka K, Takahashi T.
- International journal of hematology.Int J Hematol.2006 Dec;84(5):413-6.
- A 59-year-old woman was diagnosed with essential thrombocythemia in 1988 and had been treated with hydroxyurea, mitobronitol, busulfan, and ranimustine, in that order. Hepatosplenomegaly, low-grade fever, and body weight loss manifested, and a few blasts were noted in the peripheral blood studied in
- PMID 17189221
- Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia.
- Barta A1, Dénes R, Masszi T, Reményi P, Bátai A, Torbágyi E, Sipos A, Lengyel L, Jakab K, Gyódi E, Réti M, Földi J, Páldi-Haris P, Avalos M, Pálóczi K, Fekete S, Török J, Hoffer I, Jakab J, Váradi G, Kelemen E, Petrányi G.
- Acta haematologica.Acta Haematol.2001;105(2):64-70.
- A non-myeloablative conditioning protocol containing dibromomannitol (DBM/cytosine arabinoside/cyclophosphamide) has been applied to 36 chronic myeloid leukemia (CML) patients followed by bone marrow transplantation (BMT) from sibling donors. Risk factors include: accelerated phase (10 patients), ol
- PMID 11408706
Japanese Journal
Related Links
- Mitobronitol | C6H12Br2O4 | CID 656655 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more. ... A ...
- ATOM 12 1 X Br 27.8150 -16.7769 2 C1b C 29.0279 -17.4766 3 C1c C 30.2408 -16.7769 4 C1c C 31.4537 -17.4766 5 C1c C 32.6667 -16.7769 6 C1c C ...